Dermatitis : contact, atopic, occupational, drug最新文献_第2页

Psoriasis and Atopic Dermatitis Overlap: Pathogenesis and Therapeutic Considerations for the Clinician. 银屑病和特应性皮炎重叠：发病机制和临床治疗考虑。

IF 3.2

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-09-18 DOI: 10.1177/17103568251378145

Sammer Marzouk, Peter Lio

引用次数: 0

Allergic Contact Dermatitis to Acrylates in Samsung Galaxy® Earbuds: A Case Report. 三星Galaxy®耳塞中丙烯酸酯的过敏性接触性皮炎：一例报告。

IF 3.2

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-09-18 DOI: 10.1177/17103568251382895

Wimolsiri Iamsumang, Pranee Svetvilas, Ploychompoo Srisuwanwattana, Nathathai Pratumchart, Penpun Wattanakrai

引用次数: 0

Maintenance of Early Responses and Delayed Responses to Tralokinumab Treatment in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study. 中度至重度特应性皮炎患者对曲洛单抗治疗早期反应和延迟反应的维持：一项为期48周的真实世界研究

IF 3.2

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-09-17 DOI: 10.1177/17103568251380867

Fumisa Okano, Teppei Hagino, Akihiko Uchiyama, Keiji Kosaka, Takeshi Araki, Hidehisa Saeki, Eita Fujimoto, Sei-Ichiro Motegi, Naoko Kanda

{"title":"Maintenance of Early Responses and Delayed Responses to Tralokinumab Treatment in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study.","authors":"Fumisa Okano, Teppei Hagino, Akihiko Uchiyama, Keiji Kosaka, Takeshi Araki, Hidehisa Saeki, Eita Fujimoto, Sei-Ichiro Motegi, Naoko Kanda","doi":"10.1177/17103568251380867","DOIUrl":"https://doi.org/10.1177/17103568251380867","url":null,"abstract":" Background: An anti-interleukin-13 monoclonal antibody, tralokinumab, provided favorable efficacy and safety for atopic dermatitis (AD) in clinical trials. However, its long-term sustainability of early responses and delayed responses is unknown in real world. Objective: This study aimed to assess whether clinical outcomes achieved at week 16 of tralokinumab treatment are maintained through week 48 and whether patients without early outcomes achieve delayed outcomes. Methods: This prospective study included 143 Japanese patients with moderate-to-severe AD who received tralokinumab with topical corticosteroids. Patients who achieved an eczema area and severity index (EASI) 0f 50, EASI 75, EASI 90, EASI 100, investigator's global assessment (IGA) 0/1, or a peak pruritus-numerical rating scale (PP-NRS) 4 at week 16 were evaluated for maintenance rates of each outcome, while week 16 non-achievers were evaluated for later achievement rates at weeks 24, 36, and 48. Results: In week 16, achievers of each outcome, the week 48 maintenance rates of EASI 50, EASI 75, and EASI 90 were 100%; those of EASI 100, IGA 0/1, and PP-NRS 4 were 80.0%, 95.0%, and 90.9%, respectively. In week 16 non-achievers, week 48 achievement rates for EASI 50, EASI 75, EASI 90, and EASI 100 were 53.8%, 76.5%, 48.3%, and 12.5%, and those for IGA 0/1 and PP-NRS 4 were 45.5% and 29.6%, respectively. Conclusions: The improvements of rash or pruritus achieved at week 16 of tralokinumab treatment were mostly sustained through week 48, while some patients without early improvements achieved delayed improvements. These results support the importance of longer-term evaluation of treatment responses.","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145076932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Occupational Urticaria Caused by Opioids. 阿片类药物致职业性荨麻疹。

IF 3.2

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-09-16 DOI: 10.1177/17103568251380869

James Fuller, Ferial Ismail, Jennifer Cahill, Rosemary Nixon

引用次数: 0

Letter: Upadacitinib-Induced Amenorrhea: A Rare Adverse Effect in Atopic Dermatitis Treatment. 信：upadacitinib引起的闭经：特应性皮炎治疗中一种罕见的不良反应。

IF 3.2

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-09-15 DOI: 10.1177/17103568251380703

Qiong Gao, Chenghong Xu, Mingwei Tan, Yucheng Wang, Xiaohua Tao, Yibin Fan, Yan Teng

引用次数: 0

Transient Elevation of Eosinophil and Thymus and Activation-Regulated Chemokine Levels Associated with Cutaneous Adverse Events Due to Nemolizumab: A Case Report. 奈莫单抗引起的皮肤不良事件与嗜酸性粒细胞和胸腺的短暂升高以及激活调节的趋化因子水平相关：一个病例报告。

IF 3.2

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-09-12 DOI: 10.1177/17103568251380242

Yoshihito Mima, Masako Yamamoto, Ken Iozumi

引用次数: 0

Letter: Systemic Contact Dermatitis Caused by Metal Stent Successfully Treated With Dupilumab. 信：杜匹单抗成功治疗金属支架引起的系统性接触性皮炎。

IF 3.2

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-09-12 DOI: 10.1177/17103568251379468

Anqi Li, Kai Guan, Ran Tian, Zixi Wang

引用次数: 0

Letter: "Dupilumab for Chronic Hand Eczema: A Systematic Review and Meta-Analysis" by Riva et al. (2024). 信函：Riva等人的“Dupilumab治疗慢性手部湿疹：系统评价和荟萃分析”（2024）。

IF 3.2

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-09-12 DOI: 10.1177/17103568251376685

Raj Chovatiya, Rie von Eyben, Douglas Maslin

引用次数: 0

Letter: Lip Sunscreens: Analysis of Allergenicity and Marketing Claims. 信函：唇部防晒霜：致敏性分析和营销声明。

IF 3.2

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-09-12 DOI: 10.1177/17103568251380567

Lauren Gawey, Aditya Joshi, Camila R Marquez, Rachel Taylor, Savannah Bush, Stacey N Giuffre, Debbie Wang, Khiem A Tran, Raveena Ghanshani, Jennifer L Hsiao, Vivian Y Shi

引用次数: 0

Letter: Dermatologists Versus Skinfluencers on TikTok: Investigating the Categories, Allergenicity, and Cost of Recommended Skincare Products. 信：皮肤科医生与TikTok上的皮肤影响者：调查推荐护肤品的类别、致敏性和成本。

IF 3.2

Dermatitis : contact, atopic, occupational, drug Pub Date : 2025-09-12 DOI: 10.1177/17103568251379876

Brailyn Weber, Sarah Karels, Sara Hylwa

引用次数: 0